Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP336958.RABir3XQKAqoy1ZBgeOInii1UFBjAkpH6vvwgQGQSYR5Q130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP336958.RABir3XQKAqoy1ZBgeOInii1UFBjAkpH6vvwgQGQSYR5Q130_provenance.
• NP855818.RASB_JmoGYCAUcYGBTJmdhKRSVNMkfD0RtbLLgO6GB7oU130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP855818.RASB_JmoGYCAUcYGBTJmdhKRSVNMkfD0RtbLLgO6GB7oU130_provenance.
• NP355142.RAcXQLZkAVFPiO-fyitaIrlHZgKvgOHnIT9VdEsD_Cc18130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP355142.RAcXQLZkAVFPiO-fyitaIrlHZgKvgOHnIT9VdEsD_Cc18130_provenance.
• NP261544.RAXnXehUZ-GAQ9PSC0AmVtNZDfPifbRvjlpzbLYArSG1E130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP261544.RAXnXehUZ-GAQ9PSC0AmVtNZDfPifbRvjlpzbLYArSG1E130_provenance.
• assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP658018.RA-s8h4jA0Nhh6nK1wRuyy_G7kMUtYHyrN9LXow_UIdRY130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658018.RA-s8h4jA0Nhh6nK1wRuyy_G7kMUtYHyrN9LXow_UIdRY130_provenance.
• NP878963.RA-vMZXPdIgd6I1IpRRyANQq-8Zj8jsjEsiuoPKF9GB_Q130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP878963.RA-vMZXPdIgd6I1IpRRyANQq-8Zj8jsjEsiuoPKF9GB_Q130_provenance.
• NP927707.RA3MzCuHR8-l4Rd23l2-hHLPRWjN1Q6gV8p9YKgtbOosc130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP927707.RA3MzCuHR8-l4Rd23l2-hHLPRWjN1Q6gV8p9YKgtbOosc130_provenance.
• NP306703.RAR63gVKN5yi3Ppgqg9KRiNe34kfa7aj7EzCZEQrFbyl8130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP306703.RAR63gVKN5yi3Ppgqg9KRiNe34kfa7aj7EzCZEQrFbyl8130_provenance.
• NP554508.RAVA6FobbPs5wMbxI6vQahmou_O9ETEn4Y0Y1V7LZncHE130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP554508.RAVA6FobbPs5wMbxI6vQahmou_O9ETEn4Y0Y1V7LZncHE130_provenance.
• NP803206.RAcYZhUYtLXy5FAlvRW0kvR7IM6luqZuOANOhVJwXPZlc130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803206.RAcYZhUYtLXy5FAlvRW0kvR7IM6luqZuOANOhVJwXPZlc130_provenance.
• assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1061335.RAhaLlhLpLYDwN55AuaguyU2AoL6bJPwiU5WnZfQGp_V8130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1061335.RAhaLlhLpLYDwN55AuaguyU2AoL6bJPwiU5WnZfQGp_V8130_provenance.
• NP308156.RAzOWZWqjGbJ0fhNOoV2BJM_MBfNpZp15xHrCa0ha1V0c130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308156.RAzOWZWqjGbJ0fhNOoV2BJM_MBfNpZp15xHrCa0ha1V0c130_provenance.
• NP307598.RAFy_LYuKE2MLb1O0zeXbVvVIVw72P-inPNg6ynM0X43M130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP307598.RAFy_LYuKE2MLb1O0zeXbVvVIVw72P-inPNg6ynM0X43M130_provenance.
• NP1061332.RAH8kVzsctsri4ToV7bXN1tjLKA3gu_QKtj3_zkOZEnAI130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1061332.RAH8kVzsctsri4ToV7bXN1tjLKA3gu_QKtj3_zkOZEnAI130_provenance.
• NP1061333.RAO14-yecjlx0Nd4VhnShrj-h4Oqrnb_zqHOtk_dJegRU130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1061333.RAO14-yecjlx0Nd4VhnShrj-h4Oqrnb_zqHOtk_dJegRU130_provenance.
• NP1061334.RAEMjgd3wtTxSh5DPgS-V9x25WC6JUSHm6AqoOkPwKM2Q130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1061334.RAEMjgd3wtTxSh5DPgS-V9x25WC6JUSHm6AqoOkPwKM2Q130_provenance.
• NP1061336.RAP9YvXvxoUhEevZhh6uJOSVzxRnkNI1cr5bosKlvdqIU130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1061336.RAP9YvXvxoUhEevZhh6uJOSVzxRnkNI1cr5bosKlvdqIU130_provenance.
• NP946148.RAzHTa8SeJoYovaU2MRoKqjh68lTVDx81ZgocD94vA0rA130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946148.RAzHTa8SeJoYovaU2MRoKqjh68lTVDx81ZgocD94vA0rA130_provenance.
• NP1061327.RAySm5acLmNxeuf8Ctoj9k7ET1CPjVlAGV7zLrtnBE1U0130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1061327.RAySm5acLmNxeuf8Ctoj9k7ET1CPjVlAGV7zLrtnBE1U0130_provenance.
• NP1061329.RAzXMgQX8ZvNao-Ro1T03Ogcm8cpyo1sPhHCaf6IJ5vtA130_assertion description "[These regions harbor established oncogenes and tumor suppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B (cyclin-dependent kinase inhibitor 2B), as well as many other genes not previously reported to be involved in liver carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1061329.RAzXMgQX8ZvNao-Ro1T03Ogcm8cpyo1sPhHCaf6IJ5vtA130_provenance.